Skip to main content

Table 1 Patient characteristicsa

From: Serum microRNAs as novel biomarkers for early prediction of disease severity in patients with acute pancreatitis

  HCs (n = 52) (n = 45) MSAP (n = 42) SAP (n = 38) p
Age (years) 47.4 (17.1) 42.3 (16.9) 48.1 (15.8) 44.6 (14.7) 0.835b
Male (% total) 32 (61.5) 29 (64.3) 27 (64.3) 22 (57.9) 0.923c
Etiology (% total) 0.037c
 Gallstones 22 (48.9) 17 (40.5) 19 (50.0)
 Hyperlipidemia 15 (33.3) 13 (31.0) 18 (47.4)
 Alcohol misuse 3 (7.1)
 Other 8 (17.8) 12 (28.6) 1 (2.6)
WBC (× 109/L)d, e, f 6.0 (1.5) 10.6 (4.0) 13.0 (5.5) 13.4 (5.5) < 0.001b
CRP (mg/L)d, e, f, g, h 2.7 (2.4) 39.5 (53.6) 97.3 (83.1) 135.0 (79.3) < 0.001b
SGOT (U/L)d, e, f 20.7 (4.6) 93.8 (170.5) 120.4 (190.3) 125.0 (166.0) < 0.001b
BUN (mmol/L) 5.0 (1.0) 12.1 (48.0) 4.8 (2.1) 6.8 (6.5) 0.245b
Serum creatinine (μmol/L) 55.7 (11.1) 60.7 (19.0) 60.6 (16.7) 71.7 (55.8) 0.492b
Ranson scored, e, f, g, h, i 0.4 (0.5) 1.1 (1.0) 1.9 (1.2) 3.0 (1.4) < 0.001b
APACHE IIe, f, g, h 1.7 (1.7) 2.4 (2.0) 4.2 (2.5) 6.2 (3.9) < 0.001b
Length of stay (days)h, i 9.2 (3.2) 10.2 (4.5) 18.7 (10.7) < 0.001b
ICU admission (% total)h, i 25 (55.6) 31 (73.8) 37 (97.4) < 0.001c
Length of ICU stay (days)h, i 2.2 (2.8) 3.7 (3.7) 10.7 (6.7) < 0.001b
Need for intervention 2 27
 Surgical 1
 Interventional 2 15j
 Supportive   21j
Mortality 1
  1. aData are mean (SD) or number (%).bKruskal-Wallis Test.cFisher’s Exact Test.d-iMann-Whitney U test:dp < 0.008 between the HCand MAP groups; ep < 0.008 between the HC and MSAP groups; fp < 0.008 between the HC and SAP groups; gp < 0.008 between the MAP and MSAP groups; hp < 0.008 between the MAP and SAP groups;ip < 0.008 between the MSAP and SAP groups. j10 patients needed both interventional and supportive intervention. HC Healthy controls, MAP Mild acute pancreatitis, MSAP Moderately severe acute pancreatitis, SAP Severe acute pancreatitis, WBC White blood count, CRP C-reactive protein, SGOT Serum glutamic oxaloacetic transaminase, BUN Blood urea nitrogen, APACHE II Acute Physiology and Chronic Health Evaluation II